Frontline Therapy in CML
Sort by:
International CML Foundation
Highlights of ASH 2024: Key CML Oral Presentations
FEATURING
Timothy Hughes
- 3 views
- March 6, 2025
International CML Foundation
Highlights of ASH 2024: CML Biology Overview
FEATURING
Susan Branford
- 2 views
- March 6, 2025
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: Navigating Ambiguous Leukemia - CML-BP/MPAL
FEATURING
Justine Anderson
- 12 views
- February 6, 2025
Cleveland Clinic Taussig Cancer Institute
ASH 2024 Review: Practice-Changing Updates in the Management of CML
FEATURING
Akriti Jain
- 202 views
- February 3, 2025
- 2
Oncology 2024 Year in Review
Year in Review 2024: CML Highlights
FEATURING
Jorge Cortés
- 110 views
- January 29, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Highlights in CML
FEATURING
Jay Yang
- 322 views
- January 9, 2025
- 2
Winship Cancer Institute - Emory University
FDA Approved First Oral Solution of Imatinib
FEATURING
Aseala Abousaud
- 54 views
- December 13, 2024
- 1
International CML Foundation
ESH-iCMLf 26th Goldman Conference Highlights on CML: Biological Updates
FEATURING
Daniela Krause
- 9 views
- December 4, 2024
International CML Foundation
ESH-iCMLf 26th Goldman Conference Highlights on CML: Clinical Updates
FEATURING
Jorge Cortés
- 17 views
- December 2, 2024
Total Health
Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist
FEATURING
Sarah Medeiros
- 281 views
- November 26, 2024
- 2
ecancer
Selecting the Best Tyrosine Kinase Inhibitors for Chronic-Phase CML Patients
FEATURING
Prashant Mehta
- 17 views
- November 18, 2024
Yale Cancer Center
Myeloid Malignancies: Hot Topics in 2024
FEATURING
Nikolai Podoltsev
- 378 views
- October 21, 2024
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 39 views
- October 7, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
How I Treat R/R CML in 2024: Strategies and Emerging Therapies
FEATURING
Elias Jabbour
- 27 views
- September 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
TKI Discontinuation in CML: Defining Eligibility Criteria and Predictors of Success
FEATURING
Mohamed A. Yassin
- 31 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 585 views
- September 23, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Critical Re-Evaluation of Established Practices in CML Management
FEATURING
Hagop Kantarjian
- 189 views
- September 16, 2024
- 1
Houston Methodist
Current Treatment Landscape in Myeloid Malignancies
FEATURING
Shilpan Shah
- 63 views
- September 11, 2024
UChicago Medicine Annual Practice Updates in Hematology and Oncology
UChicago Medicine Best of ASCO® 2024: CML, AML, ALL
FEATURING
Mariam Nawas
- 45 views
- September 3, 2024
MyCancerHaven
Experts Discuss How They Use Asciminib in Their CML Practice
FEATURING
Ravi Vij,
Joshua Zeidner
- 180 views
- September 3, 2024
2024 ASCO® Annual Meeting Insights Hub
Highlights of Recent Updates in CML: Impact on Practice
FEATURING
Ehab Atallah
- 56 views
- August 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
TKI Toxicity Management in CML: A Case-Based Discussion
FEATURING
Awni Alshurafa
- 25 views
- August 15, 2024
International CML Foundation
Biological Highlights in CML From EHA
FEATURING
Nick Cross
- 50 views
- August 9, 2024